Concepedia

Leila Alland

LA

30

Publications

6.4K

Citations

20

H-Index

1994

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

Goethe University Frankfurt

Mayo Clinic in Arizona

Leila Alland is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer research.

Top concepts

Publications per year

1994–2023

30

Publications

30

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

, , +8

The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53

Jason H. Pomerantz, Nicole Schreiber‐Agus, Nanette J. Liégeois et al. · Cell · 1998 · 1.5K citations · Full text

, , +6

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein

Gregory David, Leila Alland, Suk-Hyun Hong et al. · Oncogene · 1998 · 284 citations

, , +12

Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer

Alan Keller, Robert Mennel, Vassilis A. Georgoulias et al. · Journal of Clinical Oncology · 2004 · 209 citations · Full text

Rows per page

1–5 of 30